Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 7/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 10/20 | 0.40 |
| ▸ | WNT1 | P04628 | 6/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2015117 | 0.87 | DYRK1A (0.54) | METRPS6KA3GSK3BGABRA1TMEM97 | |
| SCHEMBL2011282 | 0.81 | WNT1 (0.52) | METRPS6KA3GSK3BGABRA1TMEM97 | |
| SCHEMBL4989580 | 0.81 | EGLN1 (0.45) | GABRA1TMEM97EGLN1ACKR3 | |
| SCHEMBL2012517 | 0.79 | MET (0.55) | METRPS6KA3GABRA1TMEM97 | |
| SCHEMBL2008387 | 0.76 | MET (0.58) | METRPS6KA3GABRA1TMEM97 | |
| SCHEMBL2010519 | 0.76 | MET (0.58) | METRPS6KA3GABRA1TMEM97 | |
| SCHEMBL4436577 | 0.75 | MET (0.55) | METRPS6KA3GABRA1TMEM97 | |
| SCHEMBL9906870 | 0.74 | WNT1 (0.46) | METRPS6KA3GSK3BGABRA1TMEM97 | |
| SCHEMBL2008675 | 0.73 | MET (0.55) | METRPS6KA3GABRA1TMEM97 | |
| SCHEMBL4994253 | 0.71 | MET (0.48) | METRPS6KA3GABRA1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121608-B1 | DIHYDROPYRIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | BAYER IP GMBH (DE) | 2012-11-14 | — | — | EP | claimed |
| US-20080176833-A1 | DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-07-24 | — | — | US | claimed |
| EP-2121608-B1 | DIHYDROPYRIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | BAYER IP GMBH (DE) | 2012-11-14 | — | — | EP | disclosed |
| US-8198456-B2 | e.g. 1,4-dihydro-4-(1H-indazol-5-yl)-2,6-dimethyl-3,5-pyridinedicarbonitrile; c-Met tyrosine kinase inhibitor; antitumor agent; lung, liver, gastric and breast solid tumors; pancreatic cancer, glioma, and hepatocellular carcinoma | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-20080176833-A1 | DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176833-A1 | DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS | MET, DMPK, RET | MET 1/4885RPS6KA3 146/4885GSK3B 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.